Enterprise Value

2.045B

Cash

330.3M

Avg Qtr Burn

-48.55M

Short % of Float

13.64%

Insider Ownership

3.44%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KRESLADI (Marnetegragene autotemcel) /RP-L201 Details
Immunodeficiency, Leukocyte Adhesion Deficiency

BLA

Resubmission

RP-L102 Details
Blood disorder, Rare diseases, Fanconi Anemia

BLA

Submission

RP-A501 Details
Immunodeficiency, Danon Disease

Phase 2

Data readout

RP-L301 Details
Pyruvate Kinase Deficiency

Phase 2

Initiation

RP-A601 Details
Heart disease, Arrhythmogenic cardiomyopathy

Phase 1

Data readout

RP-L401 Details
Infantile Malignant Osteopetrosis

Failed

Discontinued